Would you consider adjuvant capecitabine in a premenopausal patient with HR-positive inflammatory breast cancer who had residual disease after neoadjuvant chemotherapy?
Answer from: Medical Oncologist at Academic Institution
Yes, I would consider adjuvant capecitabine for a patient with residual invasive disease after standard neoadjuvant chemotherapy (NAC) for HR+ inflammatory breast cancer. Given the uncertainties about the absolute benefit in recurrence and mortality in this specific situation, I would discuss this w...
Comments
Medical Oncologist at Virginia Cancer Spclsts PC I would probably not, since starting xeloda would ...
Medical Oncologist at NYU Winthrop Hospital I will not.
The data is for residual disease in t...
Medical Oncologist at St Lukes Cancer Care Assocs I agree with Drs. @Ajay Dar and @Mohammed F. Ali.&...
I would probably not, since starting xeloda would ...
I will not. The data is for residual disease in t...
I agree with Drs. @Ajay Dar and @Mohammed F. Ali.&...